XLV Full Analysis — Healthcare Emperor ETF: The Case For and Against Buying Now
⚠️ This content is for informational purposes only and does not constitute a buy or sell recommendation. The investor bears full responsibility for investment outcomes.
① Overview
XLV (Health Care Select Sector SPDR Fund) is a flagship healthcare sector ETF managed by State Street Global Advisors (SSGA). It tracks the Health Care Select Sector Index, comprising 61 S&P 500 healthcare companies, with approximately $38 billion in AUM (SSGA IR, 2025-Q4) and a total expense ratio of 0.09% — among the lowest in its category. Listed in 1998, it ranks #1 in healthcare ETF liquidity.
② TOP 10 Holdings (Based on official SSGA disclosure, accessed 2026-05-25)
| Rank | Ticker | Weight (%) | Segment |
|---|---|---|---|
| 1 | Eli Lilly (LLY) | 12.8 | Pharma (GLP-1) |
| 2 | UnitedHealth (UNH) | 10.6 | Health Insurance |
| 3 | J&J (JNJ) | 8.2 | Diversified Healthcare |
| 4 | AbbVie (ABBV) | 7.1 | Biotech |
| 5 | Merck (MRK) | 5.9 | Pharma (Keytruda) |
| 6 | Thermo Fisher (TMO) | 4.7 | Life Science Equipment |
| 7 | Abbott (ABT) | 4.3 | Medical Devices |
| 8 | Intuitive Surgical (ISRG) | 3.9 | Surgical Robotics |
| 9 | Boston Scientific (BSX) | 3.4 | Cardiovascular Devices |
| 10 | Cigna (CI) | 2.8 | Health Insurance |
| TOP 10 Total | 63.7 |
③ Cost · Tracking Difference · Tax
| Item | Figure |
|---|---|
| Expense Ratio | 0.09% |
| Intraday NAV Spread (avg.) | ±0.04% |
| Dividend Yield | ~1.4% |
| Dividend Tax (W-8BEN filed) | 15% (Korea–U.S. Tax Treaty) |
| Effective Total Annual Cost | ≈0.30% |
(Sources: Morningstar / IRS Tax Treaty List, accessed 2026-05-25)
④ Returns · MDD
| Period | XLV CAGR | SPY CAGR |
|---|---|---|
| 2026 YTD | -3.22% | -0.29% |
| 1Y (est.) | +5.6% | +5.1% |
| 3Y (est.) | +3.8% | +9.2% |
| 5Y (est.) | +7.3% | +12.6% |
- 2026 YTD MDD: -10.47% (Supabase etf_prices, 2026-01-02–2026-05-25)
- 2022 Bear Market MDD: -21.5% / 2020 COVID MDD: -29.4% (Morningstar estimates, accessed 2026-05-25)
1Y·3Y·5Y CAGR figures are Morningstar estimates. The DB holds 2026 YTD data only.
⑤ Risks
GLP-1 Concentration Risk: LLY (12.8%) is directly tied to the success of Mounjaro and Zepbound. If competition enters or adverse events emerge, a single-stock shock can drag down the entire ETF.
Dual Insurer Exposure: UNH (10.6%) + CI (2.8%) = 13.4% are simultaneously exposed to insurance regulation pressure. Tightening drug pricing and insurance regulations can hit both sectors within XLV in opposite directions — a paradoxical structure.
⚡ Counter-consensus — The Trap of "61-Stock Diversification": The combined weight of the top 5 holdings (LLY + UNH + JNJ + ABBV + MRK) is 44.6%. The sense of security from the number "61" effectively masks the actual concentration risk in 5 companies. This is less a diversified ETF and more a concentrated position in 5 major U.S. pharmaceutical and insurance names.
⑥ Comparable ETF Comparison
| ETF | Expense Ratio | # Holdings | Key Difference |
|---|---|---|---|
| XLV (SSGA) | 0.09% | 61 | S&P 500 large-cap / #1 liquidity |
| VHT (Vanguard) | 0.10% | ~410 | Includes small/mid-cap biotech |
| FHLC (Fidelity) | 0.08% | ~460 | Lowest expense ratio |
| IHF (BlackRock) | 0.40% | ~40 | Concentrated in insurance & managed care |
(Source: Morningstar ETF Comparison, accessed 2026-05-25)
⚠️ Disclaimer: Past performance does not guarantee future results. MC AI Labs is not a registered investment advisor.